EXTRAWELL PHAR (00858) announces that it is expected to achieve a mid-term profit of approximately HK$100 million to HK$105 million, turning a loss into a profit on a year-on-year basis.
Excellent Pharmaceutical (00858) announced that the group expects to achieve profitability for the six months ending September 30, 2024.
EXTRAWELL PHAR (00858) has announced that the group is expected to achieve a profit of approximately HK$100 million to HK$105 million for the six months ending on September 30, 2024, compared to a loss for the same period ending on September 30, 2023. The expected turnaround from loss to profit for this period is mainly due to non-cash items, specifically income generated from fair value changes in financial assets recognized in the income statement, as opposed to losses from fair value changes in the same non-cash items for the corresponding period in 2023.
Related Articles

GREAT CHI HLDGS (00021): Wong Man Hei appointed as a new member of the nomination committee

Shandong Sito Bio-technology (300583.SZ): The chemical raw material drug budenide passed the drug GMP compliance inspection.

CH AGRI-PROD EX (00149) releases annual performance, with a net profit attributable to shareholders of 7.8 million Hong Kong dollars, an increase of 5.4% year-on-year.
GREAT CHI HLDGS (00021): Wong Man Hei appointed as a new member of the nomination committee

Shandong Sito Bio-technology (300583.SZ): The chemical raw material drug budenide passed the drug GMP compliance inspection.

CH AGRI-PROD EX (00149) releases annual performance, with a net profit attributable to shareholders of 7.8 million Hong Kong dollars, an increase of 5.4% year-on-year.

RECOMMEND

Trump Signals End to Trade Talks, Vows to Impose Tariffs Unilaterally Ahead of July 9 Deadline
30/06/2025

One License Unlocks HKD 23.4 Billion Surge: Unpacking Hong Kong’s Ambitions as a Global Virtual Asset Hub
30/06/2025

16 Companies Submit IPO Applications in One Day; Hong Kong IPO Fundraising Hits Three-Year High
30/06/2025